GlassScriptPhysician profile
Elon Knoll
NPI 1275859704
$653.72
in general payments reported to CMS, 2019-2025
20 companies · $57.79 in 2025
The $57.79 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2021: $11.92 · 2022: $117 · 2023: $38.58 · 2024: $43.19 · 2025: $57.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125 · Education: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.27 |
| Education | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $95.00 | 2022 | |
| Amgen INC. | $67.12 | 2019 | |
| Astellas Pharma US INC | $52.79 | 2023-2025 | Xtandi, Padcev, Xospata |
| E.R. Squibb & Sons, L.L.C. | $46.12 | 2019 | |
| Genzyme Corporation | $40.53 | 2019 | |
| Pfizer INC. | $36.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $32.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.89 | 2019 | |
| Exelixis INC. | $30.85 | 2019 | |
| Kyowa Kirin, INC. | $26.35 | 2019 | |
| Gilead Sciences, INC. | $24.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.66 | 2019 | |
| Blueprint Medicines Corporation | $24.29 | 2023 | Ayvakit |
| Genmab U.S., INC. | $23.66 | 2024 | Epkinly |
| Sirtex Medical INC | $22.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.64 | 2019 | |
| Celgene Corporation | $14.94 | 2019 | |
| Glaxosmithkline, LLC. | $14.57 | 2025 | Blenrep, Ojjaara |
| Incyte Corporation | $13.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elon Knoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.